logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • May 20, 2015

PharmaCyte Biotech Creates Faster Path to the Clinic for Company's Diabetes Treatment

  • May 6, 2015

PharmaCyte Biotech's Melligen Cells Prove Safe in First Preclinical Test

  • Apr 23, 2015

PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials

  • Apr 20, 2015

PharmaCyte Biotech Finalizes International Diabetes Consortium to Cure Diabetes

  • Apr 14, 2015

PharmaCyte Biotech Appoints Former Pfizer and Alchemia Executive to Board of Directors

  • Apr 10, 2015

New Research Shows PharmaCyte Biotech's Melligen Cell Line Can Reverse Diabetes

  • Mar 27, 2015

PharmaCyte Biotech on Track to Commence Clinical Trials

  • Mar 18, 2015

PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status

  • Mar 16, 2015

PharmaCyte Biotech Provides Update on Corporate Developments and Progress With Cancer and Diabetes Programs

  • Mar 9, 2015

PharmaCyte Biotech Announces Launch of New Corporate Website

RSS
  • « Previous
  • 1...
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share May 11, 2023
  • PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan February 2, 2023